Tim Dyer is a Co-Founder, Director and Chief Executive Officer of Addex Therapeutics and a seasoned life sciences executive with more than two decades of leadership experience spanning finance, corporate development and company building. Since co-founding Addex in 2002 he has driven the company's strategic growth and execution, including its IPO and Nasdaq listing, key industry partnerships and a pipeline of allosteric modulators targeting neurological disorders. Mr. Dyer led the spin-out of Neurosterix from Addex, serving as its CEO/CFO until May 2025. Earlier he spent ten years with PricewaterhouseCoopers in the UK and Switzerland in the audit and business advisory group. He also serves as a Board Director of Neurosterix, Chairman of Stalicla SA (a clinical-stage precision-medicine company focused on neurodevelopmental disorders) and a Board Director of Multiwave Technologies AG. He was remunerated for his role as Chief Executive Officer from November 1, 2025. Mr. Dyer is a UK Chartered Accountant and holds a BSc (Hons) in Biochemistry and Pharmacology from the University of Southampton.